Company intelligence / Profile preview
Provecs Medical
Hamburg, Hamburg, Germanyprovecs.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Provecs Medical is developing ENVIRO, a patented adenoviral gene therapy platform enabling targeted delivery of up to four biologicals in one product; its lead candidate Immunalon expresses interleukin-12, interleukin-2, and CD137 ligand to modulate the tumor microenvironment by turning off tumor-mediated immune suppression and promoting T‑cell infiltration in solid tumors, including bladder cancer in partnership with Medac.
- Therapeutic areas
- Oncology
- Modalities
- Gene therapyOncolytic virus therapyVaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Medac Gesellschaft für klinische Spezialpräparate mbH (development partnership in urinary bladder cancer for Immunalon)
Beyond the preview
Go deeper on Provecs Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Provecs Medical.